Decision spine
Frames the controlling thesis, evidence status, buyer implications, and research-use limits.
Cardiovascular
Zemi Dossier
Research-use only
Genetic Cardiomyopathy Precision Therapies
A decision package on matching cardiomyopathy variants to the right therapeutic modality before buyers overgeneralize from gene name or biomarker movement.
Decision this dossier helps answer
Which genetic cardiomyopathy programs match mechanism, modality, delivery, safety window, and evidentiary standard well enough to advance?
Problem this dossier solves
The variant’s mechanism selects the modality.
The dossier argues that precision cardiomyopathy strategy breaks when buyers treat all variants in a gene as interchangeable. It connects mechanism, delivery, durability, safety window, and evidence standard into one decision surface.
What is moving: current field evidence and platform activity
What is unresolved: decision-grade proof, endpoint logic, and failure modes
What Zemi solves: evidence-gated next-study strategy
Full decision package
110-page research report plus 39-sheet Evidence & Decision Workbook
Buy now
$3,500$5,500Launch price
Controlling thesis
The variant’s mechanism selects the modality.
The dossier argues that precision cardiomyopathy strategy breaks when buyers treat all variants in a gene as interchangeable. It connects mechanism, delivery, durability, safety window, and evidence standard into one decision surface.
A Zemi Dossier turns uncertain emerging research into a decision package: what is known, what is inferred, what is hypothetical, what would falsify the thesis, and what should be built, funded, avoided, monitored, or validated next.
Research report preview
First 30 pages of the actual Genetic Cardiomyopathy Precision Therapies research report.
The public page shows the real document style, density, evidence posture, and decision framing before a buyer requests access to the full Zemi Dossier package.
Research report
The research report is the argument. It is not the whole product.
The PDF research report is the structured argument: field status, evidence maturity, buyer implications, falsifiable hypotheses, power-calculated next studies, strategic recommendations, limitations, and traceability posture.
Inspectable infrastructure
Pairs the report with claim ledgers, evidence tables, power rows, audit surfaces, and decision tools.
Executable next studies
Links hypotheses to endpoint logic, assumptions, sample-size logic, budget, and timeline planning.
Research report table of contents
Public TOC generated from the source report.
The full research report is delivered as a licensed PDF. This table shows the decision structure without publishing the full product.
| Section | What it covers | Buyer value |
|---|---|---|
| Decision Brief Read This First | Turns the report into immediate buyer triage: what matters now, what is still uncertain, and what to do next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Executive Summary | Condenses the dossier thesis, evidence posture, buyer implications, and next-study priorities. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Current Signal Refresh | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Scope and Evidence Integrity Statement | Defines the evidence window, source boundaries, research-use limits, and labeling discipline. | Lets the buyer audit support strength before relying on the package. |
| Denominator definitions and the discipline that bounds every claim | Defines the populations, measurements, or comparison bases needed to interpret evidence without overgeneralizing. | Lets the buyer audit support strength before relying on the package. |
| Intended users, and what this dossier is not | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Decision Snapshot Overview | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Reading the snapshot | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The immediate next decision, by stakeholder | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Buyer Decision Cheat Sheet | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Program-by-program decision logic, with the readout that flips each verdict | Links claims to source support so users can separate what is known, inferred, and hypothetical. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Allocation by development stage | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Source Quality Dashboard | Shows how strong the source base is and where conclusions depend on indirect or thinner support. | Lets the buyer audit support strength before relying on the package. |
| The Cardiac Translation Yield Ledger | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The Five Discoveries | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Discovery 1 - The protein-benefit decoupling is a two-threshold law, not noise | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Discovery 2 - The decoupling is a target error, not a measurement error | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Discovery 3 - Modality is variant-resolved, and 2026 confirmed the law gene by gene | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Discovery 4 - The dose ceiling is set by the wrong threshold | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Discovery 5 - The evidentiary inversion: build the surrogate the therapy earns | Shows how strong the source base is and where conclusions depend on indirect or thinner support. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| The Five Axis Translation Model | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Deepening the model: the Substrate-vs-Structure Two-Threshold sub-law | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| From model to tool: operationalizing the five axes as an executable classifier | Defines the governing argument and the evidence gates that would support or falsify it. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| A worked traverse of the model, program by program | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Cross Gene Cross Mechanism Convergence Map | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The convergence map, refreshed to the 2026 frontier | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Cross Domain Synthesis | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Evidence Maturity Matrix and Modality Comparison | Links claims to source support so users can separate what is known, inferred, and hypothetical. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| The maturity matrix read through the five axes, and the modality ladder in full | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Durability and safety by modality, in depth | Identifies translational, regulatory, safety, or delivery constraints that shape whether the thesis can be tested. | Shows where the thesis could fail or require more validation before action. |
| Key Findings | Summarizes the most decision-relevant findings and their implications for the dossier thesis. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Mechanism–Modality Match | Explains which biological signals matter for interpreting the field and discriminating between programs. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Evidentiary Standard | Shows how strong the source base is and where conclusions depend on indirect or thinner support. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Safety / Therapeutic Window | Defines the governing argument and the evidence gates that would support or falsify it. | Shows where the thesis could fail or require more validation before action. |
| Delivery | Identifies translational, regulatory, safety, or delivery constraints that shape whether the thesis can be tested. | Shows where the thesis could fail or require more validation before action. |
| Quantitative Evidence | Links claims to source support so users can separate what is known, inferred, and hypothetical. | Lets the buyer audit support strength before relying on the package. |
Evidence & Decision Workbook
The workbook is the decision engine.
A locked public preview of selected workbook-derived sheets: sheet structure, decision modules, power rows, traceability, and audit posture. Licensed buyers receive the full workbook files.
Read-only workbook preview with clipped values and no formulas. Licensed buyers receive the full Evidence & Decision Workbook with editable assumptions and working files.
Workbook inventory
Delivered workbook sheets.
Full inventories belong on dossier pages, not the homepage. Sheet names below are extracted from the actual workbook file.
| # | Workbook sheet | What it does |
|---|---|---|
| 1 | 1 Guide | Navigation layer for using the workbook, understanding sheet roles, and following the decision package. Public preview exposes Source run, Evidence pack. fields and clipped entries such as Claim reconciliation, 136 audited = 70 customer-facing., Independent. |
| 2 | 2 Claim Ledger | Claim-by-claim ledger showing verdicts, source support, inference status, and decision relevance. Public preview exposes claim_id, claim_text, report_section, evidence_layer fields and clipped entries such as Finding 1 — Somatic gene editing., Somatic gene. |
| 3 | 3 Evidence Table | Evidence-verification surface for checking sources, support quality, and the audit trail. Public preview exposes Identifier, Title, Authors, Journal fields and clipped entries such as PMID:42149404, Moral Attitudes on Somatic Gene., Simons JN, Locquet P,. |
| 4 | 4 Source-Support Verdicts | Independent check on whether key claims are actually supported by cited sources. Public preview exposes Ref ID, Title, Type, source_support_verdict fields and clipped entries such as PMID:39545889, Challenges in Cardiomyopathy Gene., PMID. |
| 5 | 5 Source Quality | Summary of source strength, gaps, and areas where conclusions depend on weaker evidence. Public preview exposes Total audited claims, 136, 136 fields and clipped entries such as Customer-facing (kept), Excluded, 66 (41 off-topic + 24 structural + 1.. |
| 6 | 6 Gene Scorecard | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Gene (disease), Mechanism class, Matched modality, Programs fields and clipped entries such as MYBPC3 (HCM), Haploinsufficiency, Gene addition /. |
| 7 | 7 Program Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes ALXN2350, Alexion, BAG3-DCM, Monoclonal antibody (mechanism. fields and clipped entries such as SGT-212, Solid Biosciences, Friedreich-CM. |
| 8 | 8 Modality Comparison | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Modality, Mechanism class fit, Representative asset(s), Delivery fields and clipped entries such as Gene addition (AAV transgene),. |
| 9 | 9 Five-Axis Scorecard | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Program (modality), Mechanism-Modality, Delivery, Durability fields and clipped entries such as TN-201 MYBPC3 (AAV9 add), FIH LVMI reductions; AAV9. |
| 10 | 10 Trial Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes NCT, Title, Type, Phase fields and clipped entries such as NCT03882437, A Clinical Study Evaluating a., INTERVENTIONAL. |
| 11 | 11 Immunogenicity-Safety | Captures failure modes and constraints that could invalidate or narrow a program. Public preview exposes Program, Capsid, NAb / seroprevalence, AE class fields and clipped entries such as TN-201, AAV9, ~50% undetectable NAb; 16% >1:40.. |
| 12 | 12 Biomarker-Endpoint | Tracks biomarkers or readouts that determine whether the thesis is moving toward testable evidence. Public preview exposes PLN R14del-DCM, PLN-SR clustering, SERCA2a., HF hospitalization, VT/VF,., PLN-SR clustering = candidate PD. fields and clipped entries. |
| 13 | 13 Regulatory-Designation | Tracks regulatory, endpoint, reimbursement, or qualification requirements that shape testing strategy. Public preview exposes Item, Detail, Status / date fields and clipped entries such as TN-201 (MYBPC3), Fast Track, Orphan Drug, Rare., sponsor-disclosed. |
| 14 | 14 CMC-Manufacturing | Workbook surface supporting a specific evidence, decision, study-planning, or release-control workflow. Public preview exposes Program, Capsid / serotype, Dose strategy, Potency / comparability note fields and clipped entries such as TN-201 / TN-401, AAV9. |
| 15 | 15 Figure Source Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes figure_id, file, figure_title, figure_family / engine fields and clipped entries such as F01, fig_buyer_matrix.png, Buyer decision matrix. |
| 16 | 16 Figure Attempt Ledger | Figure and numeric reproduction log for validating calculations, chart inputs, or displayed values. Public preview exposes Figure #, File, Engine, Status fields and clipped entries such as fig_buyer_matrix.png, deterministic, RENDERED. |
| 17 | 17 Hypotheses Ledger | Maps hypotheses to evidence state, falsification logic, endpoints, and next-study design. Public preview exposes ID, Tier, Hypothesis, Currency fields and clipped entries such as F1, Flagship, In PKP2-ACM, arrhythmia-burden.. |
| 18 | 18 Next Studies | Prioritizes next studies that could change the decision, including endpoints and evidence gates. Public preview exposes Study #, Question, Design (comparator + endpoint), Success / failure fields and clipped entries such as Does arrhythmia benefit plateau.,. |
| 19 | 19 Verification-Search Log | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes Full-text reading, PubMed/Europe PMC abstracts +., All 70 kept claims read & grounded fields and clipped entries such as Grade. |
| 20 | 20 Excluded Claims | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes Set, Claim text, Primary citation, Original exclusion reason fields and clipped entries such as offtopic, Vericiguat reduced. |
| 21 | 21 Salvage Ledger | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes Set, Recovered claim, Where it strengthens the dossier fields and clipped entries such as offtopic, Acoramidis, an oral TTR. |
| 22 | 22 Evidence Maturity | Evidence-verification surface for checking sources, support quality, and the audit trail. Public preview exposes Program (gene), Mechanism-Modality match, Delivery maturity, Durability evidence fields and clipped entries such as TN-201 (MYBPC3-HCM), Matched. |
| 23 | 23 Validation-Falsification | Connects proposed validation work to falsification criteria, readouts, and decision gates. Public preview exposes Thesis / hypothesis element, What CONFIRMS it, What WEAKENS it, What FALSIFIES it fields and clipped entries such as Protein-benefit decoupling. |
| 24 | 24 Traceability Cert | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes claim_id, report_section, report_page, evidence_layer fields and clipped entries such as Finding 1 — Somatic gene editing., Mechanistic. |
| 25 | 25 Score Basis | Explains how scores or ratings were assigned so the decision instrument can be inspected. Public preview exposes Mechanism-Modality Match (A1), Five-Axis; classifier, 0-4, 4=modality matched to mechanism. fields and clipped entries such as Delivery (A2),. |
| 26 | 26 Power Calculations | Power-calculation layer for assumptions, endpoint logic, computed sample sizes, and sensitivity checks. Public preview exposes hypothesis_id, study_id, endpoint, test_type fields and clipped entries such as F1, GC-VAL-01, MMM-classifier validation /.. |
| 27 | 27 Competitive Landscape | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Company, Asset, Modality, Gene / target fields and clipped entries such as Tenaya, TN-201, AAV9 gene addition. |
| 28 | MMM_Input_Template | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes A1 Mechanism-Modality Match, 0-4 (4 = modality matched to., 4 fields and clipped entries such as A2 Delivery, 0-4 (4 = cardiomyocyte delivery., A3. |
| 29 | MMM_Feature_Score | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes A1 Mechanism-Modality Match, Is the modality matched to the., 4, 1.3 fields and clipped entries such as A2 Delivery, Does enough therapeutic reach. |
| 30 | MMM_Class_Output | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Archetype [gene; axes; modality], Dominant class, 2nd class, Margin fields and clipped entries such as PKP2-ACM addition [PKP2; 4,3,2,3,2;.,. |
| 31 | MMM_Decision_Rules | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Mechanism class, Recommended modality, Primary functional endpoint, Required safety readout fields and clipped entries such as haploinsufficiency,. |
| 32 | MMM_Gene_Rules | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Gene / variant (documented form), Mechanism class, Recommended modality, Gene-addition verdict fields and clipped entries such as MYBPC3,. |
| 33 | MMM_Minimum_Assay_Panel | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Genotype + variant pathogenicity., Mechanism-Modality, Required fields and clipped entries such as Variant mechanism class (LoF /.,. |
| 34 | MMM_Archetype_Cards | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Archetype, Profile (gene; axes), Mechanism class, Matched move fields and clipped entries such as MYBPC3-HCM (TN-201), MYBPC3; high match, low. |
| 35 | MMM_Validation_Log | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Training target, Translation success. fields and clipped entries such as Held-out AUC target, >= 0.80, Failure threshold. |
| 36 | MMM_Traceability_Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes MMM element, Maps to claim/finding, Evidence ID, Figure fields and clipped entries such as Mechanism-Modality Match axis,. |
| 37 | MMM_Yield_Index | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes MechMatch gate, 1, 1 = modality matched to the., GATE - a 0 zeroes the product fields and clipped entries such as Delivery, 0.7,. |
| 38 | 37 Version Registry | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes v1.0, 2026-06-05, Initial revised build from source. fields and clipped entries such as v2.0 (premium elevation), 2026-06-13,. |
| 39 | 38 Audit Issues Log | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes ID, Issue, Status, Resolution / detail fields and clipped entries such as AI-1, Workbook genuinely executable?, RESOLVED. |
Power-calculated next studies
Power calculations are the execution bridge.
Power calculations are planning-grade research calculations for endpoint logic, assumptions, sample size, budget, and timeline. They do not prove hypotheses or constitute clinical protocol.
| Hypothesis | Primary endpoint | Test | Effect | α | Power | Computed n | Design n |
|---|---|---|---|---|---|---|---|
| F1 | MMM-classifier validation / protein-benefit decoupling — functional-o... | AUC (Hanley-McNeil, external) | 0.8 | 0.05 | 0.80 | 170 | 170 |
| F2 | MYBPC3-HCM >=15% LVMI reduction at 36 mo vs natural history | Two-proportion | 0.5 | 0.05 | 0.80 | 45 | 45 |
| F3 | Two-Threshold: arrhythmia-substrate rescue vs structural rescue at ma... | Two-proportion | 0.6 | 0.05 | 0.80 | 33 | 33 |
| F4 | Mechanism-modality law: editing rescues dominant-negative LMNA/RBM20 ... | Two-proportion | 0.7 | 0.05 | 0.80 | 14 | 14 |
| F5 | Minimized immunosuppression: SAE reduction (no added complement inhib... | Two-proportion | 0.2 | 0.05 | 0.80 | 80 | 80 |
Release audit discipline
Audit posture is part of the product.
Public pages do not publish exact audit scores. They should state the release discipline, revision posture, and limitations without implying peer review or validated clinical guidance.
Research-use decision package
Not medical advice, clinical guidance, investment advice, or a clinical protocol.
Known / inferred / hypothetical
The package separates cited evidence from inference and frontier hypothesis generation.
Audit-gated and revision-controlled
Adversarial audit checks source support, formulas, figures, limitations, and release readiness.
Buy this dossier
Full decision package — 110-page report + 39-sheet workbook
Buy now
- Decision research report (110 pages, PDF)
- Evidence & Decision Workbook (39 sheets, .xlsx) — claims, source-support verdicts, power calculations, traceability, and audit log
- Live, editable power-calculated next studies
$3,500$5,500Launch price